Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins

• Hoofdauteurs: Xiao-Qin Liu (Auteur), Hong-Yi Xin (Auteur), Yan-Ning Lyu (Auteur), Zhao-Wu Ma (Auteur), Xiao-Chun Peng (Auteur), Ying Xiang (Auteur), Ying-Ying Wang (Auteur), Zi-Jun Wu (Auteur), Jun-Ting Cheng (Auteur), Jia-Fu Ji (Auteur), Ji-Xin Zhong (Auteur), Bo-Xu Ren (Auteur), Xian-Wang Wang (Auteur), Hong-Wu Xin (Auteur)
• Formaat: Boek
• Gepubliceerd in: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Oncolytic herpes simplex viruses (oHSVs) have been approved for clinical usage and become more and more popular for tumor virotherapy. However, there are still many issues for the oHSVs used in clinics and clinical trials. The main issues are the limited anti-tumor effects, intratumor injection, and...